Slaughter and May advised Amyris, Inc on its collaboration with Yifan Pharmaceutical

08 Oct 2018

Slaughter and May advised Amyris, Inc. (Amyris) on its collaboration arrangements with a subsidiary of Yifan Pharmaceutical Co., Ltd. (Yifan). The collaboration was announced on 27 September 2018.

Amyris is an integrated renewable products company and a leader in the development and production of sustainable ingredients, delivering products and services across a number of markets, including specialty and performance chemicals, flavours and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. Yifan is one of the leading Chinese pharmaceutical companies covering innovation, R&D and manufacturing with a focus on active pharmaceutical ingredients, including nutritional products, biologics, small molecule drugs, and traditional Chinese medicine.

The collaboration is expected to be the start of a long-term relationship between Amyris and Yifan starting with the first target in nutrition for a key molecule to be developed, scaled and manufactured by Amyris.

Slaughter and May supported Amyris’ general counsel, Nicole Kelsey.

Contacts

Corporate: Chris McGaffin (partner), Ben Heron (associate), Victoria Lang (trainee); IP / IT: Susie Middlemiss (partner), David Ives (partner), Richard McDonnell (associate), Michaela Peck (associate).

 


List of all recent work